RegeneRx Biopharmaceuticals, Inc. – OTC:RGRX

Founder-led company

RegeneRx Biopharmaceuticals stock price today

$0.016
+0.01
+1042.86%
Financial Health
0
1
2
3
4
5
6
7
8
9

RegeneRx Biopharmaceuticals stock price monthly change

-28.57%
month

RegeneRx Biopharmaceuticals stock price quarterly change

-28.57%
quarter

RegeneRx Biopharmaceuticals key metrics

Market Cap
 19.52M
Enterprise value
 15.26M
P/E
 -10
EV/Sales
 132.57
EV/EBITDA
 -6.45
Price/Sales
 124.67
Price/Book
 -4.57
PEG ratio
 0.5
EPS
 N/A
Revenue
 N/A
EBITDA
 N/A
Income
 N/A
Revenue Q/Q
 -100%
Revenue Y/Y
 -50.00%
Profit margin
 -2548.4%
Oper. margin
 -1268.64%
Gross margin
 16.67%
EBIT margin
 -1268.64%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

RegeneRx Biopharmaceuticals stock price history

RegeneRx Biopharmaceuticals stock forecast

RegeneRx Biopharmaceuticals financial statements

Profit Margin

RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX): Profit margin
Dec 2022 19.19K -390.88K -2036.92%
Mar 2023 19.19K -545.78K -2844.11%
Jun 2023 0 0
Sep 2023 0 0
RGRX income statement history

Debt to Assets

RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX): Debt to assets
Dec 2022 382177 3.82M 1001.54%
Mar 2023 186810 3.93M 2104.35%
Jun 2023 0 0
Sep 2023 0 0
RGRX balance sheet history

Cash Flow

RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX): Cash Flow
Dec 2022 -187.51K 0 4.59K
Mar 2023 -189.33K 0 1.81K
Jun 2023 0 0 0
Sep 2023 0 0 0
RGRX cash flow history

RegeneRx Biopharmaceuticals alternative data

RegeneRx Biopharmaceuticals
Employees

RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX): Employee count
Aug 2023 2
Sep 2023 2
Oct 2023 2
Nov 2023 2
Dec 2023 2
Jan 2024 2
Feb 2024 2
Mar 2024 2
Apr 2024 2
May 2024 2
Jun 2024 2
Jul 2024 2

RegeneRx Biopharmaceuticals other data

RegeneRx Biopharmaceuticals
Hedge Funds Holdings Q1 2023

0.01% 0.00%
of RGRX is owned by hedge funds
1 +0
hedge funds hold RGRX stock
10K +0
shares is hold by hedge funds
RGRX hedge funds holdings changes

RegeneRx Biopharmaceuticals
Insider Trading

RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX): Insider trades (number of shares)
Period Buy Sel
Oct 2020 52200 0
Jun 2021 1850000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
CAVAZZA PAOLO 10 percent owner
 Common Stock 1,500,000 $0.2 $300,000
Purchase
FINKELSTEIN J J director, officer.. Series A Common Stock Warrant (right to buy) 56,250 $0.36 $20,250
Purchase
FINKELSTEIN J J director, officer.. Common Stock 75,000 $0.2 $15,000
Purchase
GOLDSTEIN ALLAN L director Common Stock 125,000 $0.2 $25,000
Purchase
GOLDSTEIN ALLAN L director Series A Common Stock Warrant (right to buy) 93,750 $0.36 $33,750
Purchase
BOVE MAURO director
 Common Stock Warrant (right to buy) 20,880 $0.21 $4,385
Purchase
GOLDSTEIN ALLAN L director Common Stock Warrant (right to buy) 10,440 $0.21 $2,192
Purchase
FINKELSTEIN J J director, officer.. Common Stock Warrant (right to buy) 20,880 $0.21 $4,385
Purchase
ELSEY R DON director
 Common Stock Warrant (right to buy) 15,625 $0.16 $2,500
Purchase
GOLDSTEIN ALLAN L director Common Stock Warrant (right to buy) 15,625 $0.21 $3,281
RGRX insider trading transactions

Frequently Asked Questions (FAQ)

  • What's the price of RegeneRx Biopharmaceuticals stock today?

    One share of RegeneRx Biopharmaceuticals stock can currently be purchased for approximately $0.02.

  • When is RegeneRx Biopharmaceuticals's next earnings date?

    Unfortunately, RegeneRx Biopharmaceuticals's (RGRX) next earnings date is currently unknown.

  • Does RegeneRx Biopharmaceuticals pay dividends?

    No, RegeneRx Biopharmaceuticals does not pay dividends.

  • How much money does RegeneRx Biopharmaceuticals make?

    RegeneRx Biopharmaceuticals has a market capitalization of 19.52M.

  • What is RegeneRx Biopharmaceuticals's stock symbol?

    RegeneRx Biopharmaceuticals, Inc. is traded on the OTC under the ticker symbol "RGRX".

  • What is RegeneRx Biopharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of RegeneRx Biopharmaceuticals?

    Shares of RegeneRx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are RegeneRx Biopharmaceuticals's key executives?

    RegeneRx Biopharmaceuticals's management team includes the following people:

    • Dr. Allan L. Goldstein Ph.D. Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board(age: 87, pay: $90,000)
    • Mr. J. J. Finkelstein Pres, Chief Executive Officer & Director(age: 73, pay: $83,380)

  • Is RegeneRx Biopharmaceuticals founder-led company?

    Yes, RegeneRx Biopharmaceuticals is a company led by its founder Dr. Allan L. Goldstein Ph.D..

  • How many employees does RegeneRx Biopharmaceuticals have?

    As Jul 2024, RegeneRx Biopharmaceuticals employs 2 workers.

  • When RegeneRx Biopharmaceuticals went public?

    RegeneRx Biopharmaceuticals, Inc. is publicly traded company for more then 24 years since IPO on 23 Mar 2001.

  • What is RegeneRx Biopharmaceuticals's official website?

    The official website for RegeneRx Biopharmaceuticals is regenerx.com.

  • Where are RegeneRx Biopharmaceuticals's headquarters?

    RegeneRx Biopharmaceuticals is headquartered at 15245 Shady Grove Road, Rockville, MD.

  • How can i contact RegeneRx Biopharmaceuticals?

    RegeneRx Biopharmaceuticals's mailing address is 15245 Shady Grove Road, Rockville, MD and company can be reached via phone at +30 12089191.

RegeneRx Biopharmaceuticals company profile:

RegeneRx Biopharmaceuticals, Inc.

regenerx.com
Exchange:

OTC

Full time employees:

3

Industry:

Biotechnology

Sector:

Healthcare

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

+30 12089191
15245 Shady Grove Road
Rockville, MD 20850

CIK: 0000707511
ISIN: US75886X1081
: